Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same

A technology of myelogenous leukemia and composition, which is applied in drug combination, blood disease, pharmaceutical formula, etc., and can solve the problem of not eliminating resting CML stem cells

Active Publication Date: 2017-10-17
メドパクトインコーポレーテッド
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since TKIs only target actively dividing CML cells, they do not eliminate quiescent CML stem cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
  • Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
  • Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1. Test of the combination of tyrosine kinase inhibitor and TEW-7197 on the therapeutic effect of CML

[0057] 1. Mouse Model and Preparation of CML Stem Cells

[0058] By making Scl / Tal1-tTA tg mice ( mice, Stock No.006209, Jackson Laboratory) and TRE-BCR-ABL1 transgenic mice ( mice, Stock No.006202, Jackson Laboratory) were crossed to prepare Scl / Tal1-tTA x TRE-BCR-ABL1 double transgenic (tg) mice. These mice were maintained with a supply of water containing 20 mg / L doxycycline (Sigma-Aldrich). At 5 weeks after birth, doxycycline-containing water was replaced with doxycycline-free water (doxycycline ended) to induce the expression of the BCR-ABL1 oncogene. About 2 to 5 weeks after doxycycline ended, the transgenic mice developed CML-like disease. These mice were SCL-tTA / BCR-ABL-tetO double positive mice and were referred to as tetracycline (tet) inducible "tg-CML-infected mice".

[0059] Isolation of primitive long-term (LT)-CML stem cells (CD150 + CD1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are a pharmaceutical composition for preventing or treating chronic myeloid leukemia and a method of preventing or treating chronic myeloid leukemia using the same, thereby being effectively applied to the prevention or treatment of chronic myeloid leukemia.

Description

technical field [0001] The present disclosure relates to a pharmaceutical composition for preventing or treating chronic myeloid leukemia and a method for preventing or treating chronic myelogenous leukemia using the composition. Background technique [0002] Chronic myelogenous leukemia (CML) is an abnormal myeloproliferative disease caused by abnormal expansion of clones of hematopoietic stem cells. CML is caused by the Philadelphia chromosome produced by a translocation between chromosome 9 and chromosome 22 (t(9;22)(q34;ql 1)). This chromosomal translocation results in a fusion between the ABL gene on chromosome 9 and the BCR gene on chromosome 22, and this BCR-ABL fusion gene produces a BCR-ABL fusion protein with abnormal tyrosine kinase activity. BCR-ABL tyrosine kinase induces abnormal cell division. Recently, the problem of tyrosine kinase inhibitor (TKI)-insensitive CML has emerged in CML patients after TKI therapy. Since TKIs target only actively dividing CML c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/444A61K31/506A61K31/496A61K31/5025A61P35/02
CPCA61K31/444A61K31/496A61K31/5025A61K31/506A61K2300/00A61K31/4439A61K45/06A61K31/03A61K31/4196A61P35/02A61P43/00A61P7/00A61K31/4178C07D401/14C07D403/14C07D471/04C07D487/04
Inventor 河一湖仲一仁李理荣
Owner メドパクトインコーポレーテッド
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com